Galmed Pharmaceuticals Stock Market Value
GLMD Stock | USD 2.75 0.05 1.79% |
Symbol | Galmed |
Galmed Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Galmed Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Galmed Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Galmed Pharmaceuticals.
12/05/2022 |
| 11/24/2024 |
If you would invest 0.00 in Galmed Pharmaceuticals on December 5, 2022 and sell it all today you would earn a total of 0.00 from holding Galmed Pharmaceuticals or generate 0.0% return on investment in Galmed Pharmaceuticals over 720 days. Galmed Pharmaceuticals is related to or competes with Affimed NV, Abeona Therapeutics, Akebia Ther, Kodiak Sciences, Mereo BioPharma, Adverum Biotechnologies, and Adaptimmune Therapeutics. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for ... More
Galmed Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Galmed Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Galmed Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Downside Deviation | 11.17 | |||
Information Ratio | 0.0606 | |||
Maximum Drawdown | 344.49 | |||
Value At Risk | (13.40) | |||
Potential Upside | 21.71 |
Galmed Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Galmed Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Galmed Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Galmed Pharmaceuticals historical prices to predict the future Galmed Pharmaceuticals' volatility.Risk Adjusted Performance | 0.0589 | |||
Jensen Alpha | 2.45 | |||
Total Risk Alpha | (3.51) | |||
Sortino Ratio | 0.2029 | |||
Treynor Ratio | (4.38) |
Galmed Pharmaceuticals Backtested Returns
Galmed Pharmaceuticals is out of control given 3 months investment horizon. Galmed Pharmaceuticals holds Efficiency (Sharpe) Ratio of 0.0706, which attests that the entity had a 0.0706% return per unit of risk over the last 3 months. We have collected data for thirty different technical indicators, which can help you to evaluate if expected returns of 2.66% are justified by taking the suggested risk. Use Galmed Pharmaceuticals Market Risk Adjusted Performance of (4.37), downside deviation of 11.17, and Risk Adjusted Performance of 0.0589 to evaluate company specific risk that cannot be diversified away. Galmed Pharmaceuticals holds a performance score of 5 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -0.54, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Galmed Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Galmed Pharmaceuticals is likely to outperform the market. Use Galmed Pharmaceuticals jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Galmed Pharmaceuticals.
Auto-correlation | 0.20 |
Weak predictability
Galmed Pharmaceuticals has weak predictability. Overlapping area represents the amount of predictability between Galmed Pharmaceuticals time series from 5th of December 2022 to 30th of November 2023 and 30th of November 2023 to 24th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Galmed Pharmaceuticals price movement. The serial correlation of 0.2 indicates that over 20.0% of current Galmed Pharmaceuticals price fluctuation can be explain by its past prices.
Correlation Coefficient | 0.2 | |
Spearman Rank Test | 0.55 | |
Residual Average | 0.0 | |
Price Variance | 1.36 |
Galmed Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Galmed Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Galmed Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Galmed Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Galmed Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
Timeline |
Galmed Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Galmed Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Galmed Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Galmed Pharmaceuticals stock over time.
Current vs Lagged Prices |
Timeline |
Galmed Pharmaceuticals Lagged Returns
When evaluating Galmed Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Galmed Pharmaceuticals stock have on its future price. Galmed Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Galmed Pharmaceuticals autocorrelation shows the relationship between Galmed Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Galmed Pharmaceuticals.
Regressed Prices |
Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Galmed Pharmaceuticals Correlation, Galmed Pharmaceuticals Volatility and Galmed Pharmaceuticals Alpha and Beta module to complement your research on Galmed Pharmaceuticals. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Galmed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.